vs
Apellis Pharmaceuticals, Inc.（APLS）与PERDOCEO EDUCATION Corp（PRDO）财务数据对比。点击上方公司名可切换其他公司
PERDOCEO EDUCATION Corp的季度营收约是Apellis Pharmaceuticals, Inc.的1.1倍（$211.6M vs $199.9M），PERDOCEO EDUCATION Corp同比增速更快（20.0% vs -5.9%），PERDOCEO EDUCATION Corp自由现金流更多（$37.9M vs $-14.3M），过去两年PERDOCEO EDUCATION Corp的营收复合增速更高（12.2% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Perdoceo Education是美国上市营利性教育集团，前身为职业教育公司（Career Education Corporation），旗下运营五所美国营利性大学，包括美国洲际大学、科罗拉多理工大学、南加利福尼亚大学、三叉戟国际大学及圣奥古斯丁健康科学大学，业务覆盖高等教育、职业教育及健康科学相关教育领域。
APLS vs PRDO — 直观对比
营收规模更大
PRDO
是对方的1.1倍
$199.9M
营收增速更快
PRDO
高出25.9%
-5.9%
自由现金流更多
PRDO
多$52.2M
$-14.3M
两年增速更快
PRDO
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $211.6M |
| 净利润 | $-59.0M | — |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 19.8% |
| 净利率 | -29.5% | — |
| 营收同比 | -5.9% | 20.0% |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | $0.55 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSPRDO
| Q4 25 | $199.9M | $211.6M | ||
| Q3 25 | $458.6M | $211.9M | ||
| Q2 25 | $178.5M | $209.6M | ||
| Q1 25 | $166.8M | $213.0M | ||
| Q4 24 | $212.5M | $176.4M | ||
| Q3 24 | $196.8M | $169.8M | ||
| Q2 24 | $199.7M | $166.7M | ||
| Q1 24 | $172.3M | $168.3M |
净利润APLSPRDO
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $39.9M | ||
| Q2 25 | $-42.2M | $41.0M | ||
| Q1 25 | $-92.2M | $43.7M | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-57.4M | $38.3M | ||
| Q2 24 | $-37.7M | $38.4M | ||
| Q1 24 | $-66.4M | $39.4M |
营业利润率APLSPRDO
| Q4 25 | -25.6% | 19.8% | ||
| Q3 25 | 48.7% | 24.1% | ||
| Q2 25 | -18.6% | 24.5% | ||
| Q1 25 | -50.0% | 24.3% | ||
| Q4 24 | -12.3% | 21.1% | ||
| Q3 24 | -24.0% | 26.4% | ||
| Q2 24 | -14.7% | 27.6% | ||
| Q1 24 | -36.0% | 27.5% |
净利率APLSPRDO
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | 18.8% | ||
| Q2 25 | -23.6% | 19.6% | ||
| Q1 25 | -55.3% | 20.5% | ||
| Q4 24 | -17.1% | — | ||
| Q3 24 | -29.2% | 22.5% | ||
| Q2 24 | -18.9% | 23.0% | ||
| Q1 24 | -38.5% | 23.4% |
每股收益（稀释后）APLSPRDO
| Q4 25 | $-0.40 | $0.55 | ||
| Q3 25 | $1.67 | $0.60 | ||
| Q2 25 | $-0.33 | $0.62 | ||
| Q1 25 | $-0.74 | $0.65 | ||
| Q4 24 | $-0.30 | $0.46 | ||
| Q3 24 | $-0.46 | $0.57 | ||
| Q2 24 | $-0.30 | $0.57 | ||
| Q1 24 | $-0.54 | $0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $111.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $972.4M |
| 总资产 | $1.1B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSPRDO
| Q4 25 | $466.2M | $111.0M | ||
| Q3 25 | $479.2M | $159.5M | ||
| Q2 25 | $370.0M | $172.1M | ||
| Q1 25 | $358.4M | $132.1M | ||
| Q4 24 | $411.3M | $109.1M | ||
| Q3 24 | $396.9M | $238.0M | ||
| Q2 24 | $360.1M | $127.9M | ||
| Q1 24 | $325.9M | $125.8M |
总债务APLSPRDO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSPRDO
| Q4 25 | $370.1M | $972.4M | ||
| Q3 25 | $401.2M | $997.9M | ||
| Q2 25 | $156.3M | $984.6M | ||
| Q1 25 | $164.2M | $970.3M | ||
| Q4 24 | $228.5M | $959.5M | ||
| Q3 24 | $237.1M | $935.4M | ||
| Q2 24 | $264.3M | $899.5M | ||
| Q1 24 | $266.7M | $866.1M |
总资产APLSPRDO
| Q4 25 | $1.1B | $1.2B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $821.4M | $1.3B | ||
| Q1 25 | $807.3M | $1.3B | ||
| Q4 24 | $885.1M | $1.2B | ||
| Q3 24 | $901.9M | $1.1B | ||
| Q2 24 | $904.5M | $1.1B | ||
| Q1 24 | $831.9M | $1.1B |
负债/权益比APLSPRDO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $40.1M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $37.9M |
| 自由现金流率自由现金流/营收 | -7.1% | 17.9% |
| 资本支出强度资本支出/营收 | 0.1% | 1.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $216.7M |
8季度趋势，按日历期对齐
经营现金流APLSPRDO
| Q4 25 | $-14.2M | $40.1M | ||
| Q3 25 | $108.5M | $41.2M | ||
| Q2 25 | $4.4M | $78.8M | ||
| Q1 25 | $-53.4M | $65.1M | ||
| Q4 24 | $19.4M | $17.6M | ||
| Q3 24 | $34.1M | $51.0M | ||
| Q2 24 | $-8.3M | $38.5M | ||
| Q1 24 | $-133.0M | $54.5M |
自由现金流APLSPRDO
| Q4 25 | $-14.3M | $37.9M | ||
| Q3 25 | $108.3M | $39.4M | ||
| Q2 25 | $4.4M | $76.0M | ||
| Q1 25 | $-53.4M | $63.4M | ||
| Q4 24 | $19.3M | $16.0M | ||
| Q3 24 | — | $50.0M | ||
| Q2 24 | $-8.4M | $37.7M | ||
| Q1 24 | $-133.3M | $53.3M |
自由现金流率APLSPRDO
| Q4 25 | -7.1% | 17.9% | ||
| Q3 25 | 23.6% | 18.6% | ||
| Q2 25 | 2.5% | 36.3% | ||
| Q1 25 | -32.0% | 29.8% | ||
| Q4 24 | 9.1% | 9.1% | ||
| Q3 24 | — | 29.4% | ||
| Q2 24 | -4.2% | 22.6% | ||
| Q1 24 | -77.3% | 31.7% |
资本支出强度APLSPRDO
| Q4 25 | 0.1% | 1.1% | ||
| Q3 25 | 0.0% | 0.9% | ||
| Q2 25 | 0.0% | 1.3% | ||
| Q1 25 | 0.0% | 0.8% | ||
| Q4 24 | 0.0% | 0.9% | ||
| Q3 24 | 0.0% | 0.6% | ||
| Q2 24 | 0.0% | 0.5% | ||
| Q1 24 | 0.2% | 0.7% |
现金转化率APLSPRDO
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 1.03× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | — | 1.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.33× | ||
| Q2 24 | — | 1.00× | ||
| Q1 24 | — | 1.38× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
PRDO
| CTU | $107.0M | 51% |
| AIUS | $60.8M | 29% |
| University Of St Augustine For Health Sciences Llc | $43.7M | 21% |
| Other | $1.1M | 1% |
